The inquiry centers on the company’s recent second-quarter financial report, which revealed a discrepancy in treatment billing. Although five patients received the one-time ZEVASKYN therapy, Abeona reported that only four treatments qualified for revenue recognition because one batch failed to meet the minimum sheet requirement. This disclosure prompted an immediate market reaction, pushing the company's share price down by $1.12 to close at $6.35.

Pomerantz LLP, a firm specializing in securities class action litigation, is now soliciting contact from affected shareholders. Investors who held stock during this period are encouraged to reach out to Danielle Peyton to discuss the potential for legal recourse regarding these financial disclosures and overall corporate conduct.